Pipeline Drugs

Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Posted on Updated on

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.

It is an autoimmune disorder when body’s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as “systemic onset juvenile rheumatoid arthritis”It makes the joints inflamed and stiff for more than six weeks.

DelveInsight report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of Tofacitinib pipeline drug by Pfizer Phase III. In addition to this, the report imparts information on several other drugs as well.

Key Highlights of Report:

  • Comprehensive insights about pipeline drugs across this indication
  • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages
  • Therapeutics assessment by monotherapy and combination products and molecule type drug information
  • Companies involved in therapeutic development of the products
  • Discontinued and dormant products

DelveInsight is offering the Report at a price of US 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

.

Advertisements

Metastatic Prostate Cancer-Pipeline Insights, 2014

Posted on Updated on

DelveInsight’s,“ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Prostate Cancer
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents
– Metastatic Prostate Cancer Overview
– Metastatic Prostate Cancer Pipeline Therapeutics
– Metastatic Prostate Cancer Therapeutics under Development by Companies
– Metastatic Prostate Cancer Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Metastatic Prostate Cancer Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Metastatic Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Metastatic Prostate Cancer – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Metastatic Prostate Cancer – Discontinued Products
– Metastatic Prostate Cancer – Dormant Products
– Companies Involved in Therapeutics Development for Metastatic Prostate Cancer
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type
– Metastatic Prostate Cancer Therapeutics – Discontinued Products
– Metastatic Prostate Cancer Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type

Report Pricing
Single User License: $1250
Site License:$2500
Global License:$4000

For Sample Pages and Report, please contact us at info@delveinsight.com

Brain Hemorrhage-Pipeline Insights, 2014

Posted on Updated on

DelveInsight’s, Brain Hemorrhage-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Brain Hemorrhage. This report provides information on the therapeutic development based on the Brain Hemorrhage dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Brain Hemorrhage
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Brain Hemorrhage pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Brain Hemorrhage and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Brain Hemorrhage
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Brain Hemorrhage pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents

– Brain Hemorrhage Overview
– Brain Hemorrhage Pipeline Therapeutics
– Brain Hemorrhage Therapeutics under Development by Companies
– Brain Hemorrhage Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Brain Hemorrhage Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Brain Hemorrhage Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Brain Hemorrhage Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Brain Hemorrhage – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Brain Hemorrhage – Discontinued Products
– Brain Hemorrhage – Dormant Products
– Companies Involved in Therapeutics Development for Brain Hemorrhage
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Brain Hemorrhage, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Brain Hemorrhage Assessment by Monotherapy Products
– Brain Hemorrhage Assessment by Combination Products
– Brain Hemorrhage Assessment by Route of Administration
– Brain Hemorrhage Assessment by Stage and Route of Administration
– Brain Hemorrhage Assessment by Molecule Type
– Brain Hemorrhage Assessment by Stage and Molecule Type
– Brain Hemorrhage Therapeutics – Discontinued Products
– Brain Hemorrhage Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Brain Hemorrhage, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Brain Hemorrhage Assessment by Monotherapy Products
– Brain Hemorrhage Assessment by Combination Products
– Brain Hemorrhage Assessment by Route of Administration
– Brain Hemorrhage Assessment by Stage and Route of Administration
– Brain Hemorrhage Assessment by Molecule Type
– Brain Hemorrhage Assessment by Stage and Molecule Type

Report Pricing

Single User: USD 1250
Site License: USD 2500
Global License: USD 4000

To order the Sample Pages and the Report please contact below:

Email: info@delveinsight.com

Source: DelveInsight